Novartis Announced The European Commission (Ec) Has Approved Cosentyx (Secukinumab), Used Alone Or In Combination With Methotrexate, In The Juvenile Idiopathic Arthritis (Jia) Categories Of Enthesitis-Related Arthritis (Era) And Juvenile Psoriatic Arthritis (Jpsa) In Patients 6 Years And Older Whose Disease Has Responded Inadequately To, Or Who Cannot Tolerate, Conventional Therapy.
